nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—HTR6—Raloxifene—osteoporosis	0.135	1	CbGbCtD
Loxapine—Muscle spasms—Pamidronate—osteoporosis	0.00118	0.00228	CcSEcCtD
Loxapine—Angiopathy—Zoledronate—osteoporosis	0.00117	0.00226	CcSEcCtD
Loxapine—Insomnia—Raloxifene—osteoporosis	0.00117	0.00226	CcSEcCtD
Loxapine—Mediastinal disorder—Zoledronate—osteoporosis	0.00116	0.00224	CcSEcCtD
Loxapine—Syncope—Risedronate—osteoporosis	0.00116	0.00224	CcSEcCtD
Loxapine—Insomnia—Ibandronate—osteoporosis	0.00115	0.00224	CcSEcCtD
Loxapine—Cough—Ethinyl Estradiol—osteoporosis	0.00115	0.00223	CcSEcCtD
Loxapine—Gastrointestinal disorder—Estropipate—osteoporosis	0.00115	0.00223	CcSEcCtD
Loxapine—Fatigue—Estropipate—osteoporosis	0.00115	0.00222	CcSEcCtD
Loxapine—Paraesthesia—Ibandronate—osteoporosis	0.00115	0.00222	CcSEcCtD
Loxapine—Constipation—Estropipate—osteoporosis	0.00114	0.0022	CcSEcCtD
Loxapine—Alopecia—Zoledronate—osteoporosis	0.00114	0.0022	CcSEcCtD
Loxapine—Hypersensitivity—Etidronic acid—osteoporosis	0.00113	0.0022	CcSEcCtD
Loxapine—Loss of consciousness—Risedronate—osteoporosis	0.00113	0.00219	CcSEcCtD
Loxapine—Insomnia—Calcitriol—osteoporosis	0.00113	0.00219	CcSEcCtD
Loxapine—Photosensitivity reaction—Estradiol—osteoporosis	0.00113	0.00219	CcSEcCtD
Loxapine—Weight increased—Estradiol—osteoporosis	0.00113	0.00218	CcSEcCtD
Loxapine—Agitation—Pamidronate—osteoporosis	0.00113	0.00218	CcSEcCtD
Loxapine—Cough—Risedronate—osteoporosis	0.00113	0.00218	CcSEcCtD
Loxapine—Angiopathy—Conjugated Estrogens—osteoporosis	0.00112	0.00218	CcSEcCtD
Loxapine—Constipation—Alendronate—osteoporosis	0.00112	0.00217	CcSEcCtD
Loxapine—Weight decreased—Estradiol—osteoporosis	0.00112	0.00217	CcSEcCtD
Loxapine—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.00112	0.00216	CcSEcCtD
Loxapine—Gastrointestinal disorder—Raloxifene—osteoporosis	0.00111	0.00216	CcSEcCtD
Loxapine—Hypertension—Risedronate—osteoporosis	0.00111	0.00216	CcSEcCtD
Loxapine—Somnolence—Calcitriol—osteoporosis	0.00111	0.00215	CcSEcCtD
Loxapine—Gastrointestinal disorder—Ibandronate—osteoporosis	0.0011	0.00213	CcSEcCtD
Loxapine—Fatigue—Ibandronate—osteoporosis	0.0011	0.00213	CcSEcCtD
Loxapine—Syncope—Pamidronate—osteoporosis	0.0011	0.00213	CcSEcCtD
Loxapine—Chest pain—Risedronate—osteoporosis	0.0011	0.00213	CcSEcCtD
Loxapine—Leukopenia—Pamidronate—osteoporosis	0.0011	0.00212	CcSEcCtD
Loxapine—Dysgeusia—Zoledronate—osteoporosis	0.0011	0.00212	CcSEcCtD
Loxapine—Alopecia—Conjugated Estrogens—osteoporosis	0.00109	0.00212	CcSEcCtD
Loxapine—Constipation—Ibandronate—osteoporosis	0.00109	0.00211	CcSEcCtD
Loxapine—Pruritus—Etidronic acid—osteoporosis	0.00109	0.00211	CcSEcCtD
Loxapine—Feeling abnormal—Alendronate—osteoporosis	0.00108	0.00209	CcSEcCtD
Loxapine—Oedema—Ethinyl Estradiol—osteoporosis	0.00108	0.00209	CcSEcCtD
Loxapine—Loss of consciousness—Pamidronate—osteoporosis	0.00108	0.00209	CcSEcCtD
Loxapine—Muscle spasms—Zoledronate—osteoporosis	0.00108	0.00208	CcSEcCtD
Loxapine—Jaundice—Estradiol—osteoporosis	0.00108	0.00208	CcSEcCtD
Loxapine—Dry mouth—Risedronate—osteoporosis	0.00107	0.00208	CcSEcCtD
Loxapine—Cough—Pamidronate—osteoporosis	0.00107	0.00207	CcSEcCtD
Loxapine—Constipation—Calcitriol—osteoporosis	0.00107	0.00207	CcSEcCtD
Loxapine—Convulsion—Pamidronate—osteoporosis	0.00106	0.00206	CcSEcCtD
Loxapine—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.00106	0.00205	CcSEcCtD
Loxapine—Hypertension—Pamidronate—osteoporosis	0.00106	0.00205	CcSEcCtD
Loxapine—Tension—Conjugated Estrogens—osteoporosis	0.00106	0.00205	CcSEcCtD
Loxapine—Dysgeusia—Conjugated Estrogens—osteoporosis	0.00106	0.00204	CcSEcCtD
Loxapine—Vision blurred—Zoledronate—osteoporosis	0.00106	0.00204	CcSEcCtD
Loxapine—Feeling abnormal—Ibandronate—osteoporosis	0.00105	0.00204	CcSEcCtD
Loxapine—Tremor—Zoledronate—osteoporosis	0.00105	0.00203	CcSEcCtD
Loxapine—Muscle spasms—Conjugated Estrogens—osteoporosis	0.00104	0.00201	CcSEcCtD
Loxapine—Shock—Risedronate—osteoporosis	0.00104	0.002	CcSEcCtD
Loxapine—Nervous system disorder—Risedronate—osteoporosis	0.00103	0.002	CcSEcCtD
Loxapine—Agitation—Zoledronate—osteoporosis	0.00103	0.00199	CcSEcCtD
Loxapine—Vision blurred—Conjugated Estrogens—osteoporosis	0.00102	0.00197	CcSEcCtD
Loxapine—Confusional state—Pamidronate—osteoporosis	0.00101	0.00195	CcSEcCtD
Loxapine—Syncope—Zoledronate—osteoporosis	0.001	0.00194	CcSEcCtD
Loxapine—Leukopenia—Zoledronate—osteoporosis	0.001	0.00194	CcSEcCtD
Loxapine—Oedema—Pamidronate—osteoporosis	0.001	0.00194	CcSEcCtD
Loxapine—Hepatitis—Estradiol—osteoporosis	0.000991	0.00192	CcSEcCtD
Loxapine—Hypoaesthesia—Estradiol—osteoporosis	0.000986	0.00191	CcSEcCtD
Loxapine—Shock—Pamidronate—osteoporosis	0.000984	0.00191	CcSEcCtD
Loxapine—Loss of consciousness—Zoledronate—osteoporosis	0.000984	0.00191	CcSEcCtD
Loxapine—Hypersensitivity—Estropipate—osteoporosis	0.000981	0.0019	CcSEcCtD
Loxapine—Nervous system disorder—Pamidronate—osteoporosis	0.000981	0.0019	CcSEcCtD
Loxapine—Thrombocytopenia—Pamidronate—osteoporosis	0.00098	0.0019	CcSEcCtD
Loxapine—Vomiting—Etidronic acid—osteoporosis	0.000979	0.0019	CcSEcCtD
Loxapine—Cough—Zoledronate—osteoporosis	0.000977	0.00189	CcSEcCtD
Loxapine—Tachycardia—Pamidronate—osteoporosis	0.000976	0.00189	CcSEcCtD
Loxapine—Rash—Etidronic acid—osteoporosis	0.000971	0.00188	CcSEcCtD
Loxapine—Convulsion—Zoledronate—osteoporosis	0.00097	0.00188	CcSEcCtD
Loxapine—Dermatitis—Etidronic acid—osteoporosis	0.00097	0.00188	CcSEcCtD
Loxapine—Syncope—Conjugated Estrogens—osteoporosis	0.000967	0.00187	CcSEcCtD
Loxapine—Hypertension—Zoledronate—osteoporosis	0.000967	0.00187	CcSEcCtD
Loxapine—Hypersensitivity—Alendronate—osteoporosis	0.000966	0.00187	CcSEcCtD
Loxapine—Headache—Etidronic acid—osteoporosis	0.000964	0.00187	CcSEcCtD
Loxapine—Asthenia—Estropipate—osteoporosis	0.000955	0.00185	CcSEcCtD
Loxapine—Chest pain—Zoledronate—osteoporosis	0.000953	0.00185	CcSEcCtD
Loxapine—Insomnia—Risedronate—osteoporosis	0.000952	0.00184	CcSEcCtD
Loxapine—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000948	0.00183	CcSEcCtD
Loxapine—Paraesthesia—Risedronate—osteoporosis	0.000945	0.00183	CcSEcCtD
Loxapine—Pruritus—Estropipate—osteoporosis	0.000942	0.00182	CcSEcCtD
Loxapine—Asthenia—Alendronate—osteoporosis	0.000941	0.00182	CcSEcCtD
Loxapine—Hypersensitivity—Ibandronate—osteoporosis	0.000941	0.00182	CcSEcCtD
Loxapine—Cough—Conjugated Estrogens—osteoporosis	0.000941	0.00182	CcSEcCtD
Loxapine—Dyspnoea—Risedronate—osteoporosis	0.000938	0.00182	CcSEcCtD
Loxapine—Hypotension—Pamidronate—osteoporosis	0.000935	0.00181	CcSEcCtD
Loxapine—Convulsion—Conjugated Estrogens—osteoporosis	0.000934	0.00181	CcSEcCtD
Loxapine—Dry mouth—Zoledronate—osteoporosis	0.000932	0.00181	CcSEcCtD
Loxapine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000932	0.0018	CcSEcCtD
Loxapine—Fatigue—Ethinyl Estradiol—osteoporosis	0.000931	0.0018	CcSEcCtD
Loxapine—Pruritus—Alendronate—osteoporosis	0.000928	0.0018	CcSEcCtD
Loxapine—Constipation—Ethinyl Estradiol—osteoporosis	0.000923	0.00179	CcSEcCtD
Loxapine—Confusional state—Zoledronate—osteoporosis	0.000921	0.00178	CcSEcCtD
Loxapine—Hypersensitivity—Calcitriol—osteoporosis	0.000921	0.00178	CcSEcCtD
Loxapine—Chest pain—Conjugated Estrogens—osteoporosis	0.000918	0.00178	CcSEcCtD
Loxapine—Asthenia—Ibandronate—osteoporosis	0.000916	0.00177	CcSEcCtD
Loxapine—Nausea—Etidronic acid—osteoporosis	0.000914	0.00177	CcSEcCtD
Loxapine—Oedema—Zoledronate—osteoporosis	0.000914	0.00177	CcSEcCtD
Loxapine—Gastrointestinal disorder—Risedronate—osteoporosis	0.000909	0.00176	CcSEcCtD
Loxapine—Fatigue—Risedronate—osteoporosis	0.000907	0.00176	CcSEcCtD
Loxapine—Insomnia—Pamidronate—osteoporosis	0.000905	0.00175	CcSEcCtD
Loxapine—Pruritus—Ibandronate—osteoporosis	0.000903	0.00175	CcSEcCtD
Loxapine—Constipation—Risedronate—osteoporosis	0.0009	0.00174	CcSEcCtD
Loxapine—Angiopathy—Estradiol—osteoporosis	0.000899	0.00174	CcSEcCtD
Loxapine—Shock—Zoledronate—osteoporosis	0.000899	0.00174	CcSEcCtD
Loxapine—Paraesthesia—Pamidronate—osteoporosis	0.000898	0.00174	CcSEcCtD
Loxapine—Asthenia—Calcitriol—osteoporosis	0.000897	0.00174	CcSEcCtD
Loxapine—Nervous system disorder—Zoledronate—osteoporosis	0.000896	0.00174	CcSEcCtD
Loxapine—Thrombocytopenia—Zoledronate—osteoporosis	0.000895	0.00173	CcSEcCtD
Loxapine—Mediastinal disorder—Estradiol—osteoporosis	0.000893	0.00173	CcSEcCtD
Loxapine—Dyspnoea—Pamidronate—osteoporosis	0.000892	0.00173	CcSEcCtD
Loxapine—Tachycardia—Zoledronate—osteoporosis	0.000892	0.00173	CcSEcCtD
Loxapine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000889	0.00172	CcSEcCtD
Loxapine—Somnolence—Pamidronate—osteoporosis	0.000889	0.00172	CcSEcCtD
Loxapine—Pruritus—Calcitriol—osteoporosis	0.000884	0.00171	CcSEcCtD
Loxapine—Dizziness—Estropipate—osteoporosis	0.000881	0.00171	CcSEcCtD
Loxapine—Oedema—Conjugated Estrogens—osteoporosis	0.00088	0.0017	CcSEcCtD
Loxapine—Alopecia—Estradiol—osteoporosis	0.000876	0.0017	CcSEcCtD
Loxapine—Dizziness—Alendronate—osteoporosis	0.000867	0.00168	CcSEcCtD
Loxapine—Shock—Conjugated Estrogens—osteoporosis	0.000866	0.00168	CcSEcCtD
Loxapine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000864	0.00167	CcSEcCtD
Loxapine—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000863	0.00167	CcSEcCtD
Loxapine—Fatigue—Pamidronate—osteoporosis	0.000863	0.00167	CcSEcCtD
Loxapine—Tachycardia—Conjugated Estrogens—osteoporosis	0.000859	0.00166	CcSEcCtD
Loxapine—Constipation—Pamidronate—osteoporosis	0.000855	0.00166	CcSEcCtD
Loxapine—Hypotension—Zoledronate—osteoporosis	0.000854	0.00165	CcSEcCtD
Loxapine—Dizziness—Raloxifene—osteoporosis	0.000853	0.00165	CcSEcCtD
Loxapine—Tension—Estradiol—osteoporosis	0.000847	0.00164	CcSEcCtD
Loxapine—Vomiting—Estropipate—osteoporosis	0.000847	0.00164	CcSEcCtD
Loxapine—Dysgeusia—Estradiol—osteoporosis	0.000845	0.00164	CcSEcCtD
Loxapine—Dizziness—Ibandronate—osteoporosis	0.000844	0.00164	CcSEcCtD
Loxapine—Rash—Estropipate—osteoporosis	0.00084	0.00163	CcSEcCtD
Loxapine—Dermatitis—Estropipate—osteoporosis	0.000839	0.00162	CcSEcCtD
Loxapine—Headache—Estropipate—osteoporosis	0.000834	0.00162	CcSEcCtD
Loxapine—Vomiting—Alendronate—osteoporosis	0.000834	0.00161	CcSEcCtD
Loxapine—Muscle spasms—Estradiol—osteoporosis	0.00083	0.00161	CcSEcCtD
Loxapine—Rash—Alendronate—osteoporosis	0.000827	0.0016	CcSEcCtD
Loxapine—Insomnia—Zoledronate—osteoporosis	0.000826	0.0016	CcSEcCtD
Loxapine—Dermatitis—Alendronate—osteoporosis	0.000826	0.0016	CcSEcCtD
Loxapine—Feeling abnormal—Pamidronate—osteoporosis	0.000824	0.0016	CcSEcCtD
Loxapine—Hypotension—Conjugated Estrogens—osteoporosis	0.000822	0.00159	CcSEcCtD
Loxapine—Headache—Alendronate—osteoporosis	0.000822	0.00159	CcSEcCtD
Loxapine—Paraesthesia—Zoledronate—osteoporosis	0.000821	0.00159	CcSEcCtD
Loxapine—Vomiting—Raloxifene—osteoporosis	0.00082	0.00159	CcSEcCtD
Loxapine—Dyspnoea—Zoledronate—osteoporosis	0.000815	0.00158	CcSEcCtD
Loxapine—Rash—Raloxifene—osteoporosis	0.000813	0.00157	CcSEcCtD
Loxapine—Dermatitis—Raloxifene—osteoporosis	0.000813	0.00157	CcSEcCtD
Loxapine—Somnolence—Zoledronate—osteoporosis	0.000812	0.00157	CcSEcCtD
Loxapine—Vomiting—Ibandronate—osteoporosis	0.000812	0.00157	CcSEcCtD
Loxapine—Tremor—Estradiol—osteoporosis	0.000808	0.00157	CcSEcCtD
Loxapine—Headache—Raloxifene—osteoporosis	0.000808	0.00156	CcSEcCtD
Loxapine—Rash—Ibandronate—osteoporosis	0.000805	0.00156	CcSEcCtD
Loxapine—Dermatitis—Ibandronate—osteoporosis	0.000804	0.00156	CcSEcCtD
Loxapine—Headache—Ibandronate—osteoporosis	0.0008	0.00155	CcSEcCtD
Loxapine—Insomnia—Conjugated Estrogens—osteoporosis	0.000796	0.00154	CcSEcCtD
Loxapine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000795	0.00154	CcSEcCtD
Loxapine—Vomiting—Calcitriol—osteoporosis	0.000795	0.00154	CcSEcCtD
Loxapine—Agitation—Estradiol—osteoporosis	0.000793	0.00154	CcSEcCtD
Loxapine—Nausea—Estropipate—osteoporosis	0.000791	0.00153	CcSEcCtD
Loxapine—Paraesthesia—Conjugated Estrogens—osteoporosis	0.00079	0.00153	CcSEcCtD
Loxapine—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000789	0.00153	CcSEcCtD
Loxapine—Rash—Calcitriol—osteoporosis	0.000788	0.00153	CcSEcCtD
Loxapine—Fatigue—Zoledronate—osteoporosis	0.000788	0.00153	CcSEcCtD
Loxapine—Dermatitis—Calcitriol—osteoporosis	0.000787	0.00152	CcSEcCtD
Loxapine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000784	0.00152	CcSEcCtD
Loxapine—Headache—Calcitriol—osteoporosis	0.000783	0.00152	CcSEcCtD
Loxapine—Somnolence—Conjugated Estrogens—osteoporosis	0.000782	0.00151	CcSEcCtD
Loxapine—Constipation—Zoledronate—osteoporosis	0.000781	0.00151	CcSEcCtD
Loxapine—Nausea—Alendronate—osteoporosis	0.000779	0.00151	CcSEcCtD
Loxapine—Hypersensitivity—Risedronate—osteoporosis	0.000775	0.0015	CcSEcCtD
Loxapine—Asthenia—Ethinyl Estradiol—osteoporosis	0.000774	0.0015	CcSEcCtD
Loxapine—Syncope—Estradiol—osteoporosis	0.000774	0.0015	CcSEcCtD
Loxapine—Nausea—Raloxifene—osteoporosis	0.000766	0.00148	CcSEcCtD
Loxapine—Pruritus—Ethinyl Estradiol—osteoporosis	0.000764	0.00148	CcSEcCtD
Loxapine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.00076	0.00147	CcSEcCtD
Loxapine—Fatigue—Conjugated Estrogens—osteoporosis	0.000759	0.00147	CcSEcCtD
Loxapine—Nausea—Ibandronate—osteoporosis	0.000758	0.00147	CcSEcCtD
Loxapine—Loss of consciousness—Estradiol—osteoporosis	0.000758	0.00147	CcSEcCtD
Loxapine—Asthenia—Risedronate—osteoporosis	0.000755	0.00146	CcSEcCtD
Loxapine—Feeling abnormal—Zoledronate—osteoporosis	0.000753	0.00146	CcSEcCtD
Loxapine—Cough—Estradiol—osteoporosis	0.000753	0.00146	CcSEcCtD
Loxapine—Constipation—Conjugated Estrogens—osteoporosis	0.000752	0.00146	CcSEcCtD
Loxapine—Hypertension—Estradiol—osteoporosis	0.000745	0.00144	CcSEcCtD
Loxapine—Pruritus—Risedronate—osteoporosis	0.000745	0.00144	CcSEcCtD
Loxapine—Nausea—Calcitriol—osteoporosis	0.000743	0.00144	CcSEcCtD
Loxapine—Hypersensitivity—Pamidronate—osteoporosis	0.000737	0.00143	CcSEcCtD
Loxapine—Chest pain—Estradiol—osteoporosis	0.000735	0.00142	CcSEcCtD
Loxapine—Dry mouth—Estradiol—osteoporosis	0.000718	0.00139	CcSEcCtD
Loxapine—Asthenia—Pamidronate—osteoporosis	0.000718	0.00139	CcSEcCtD
Loxapine—Dizziness—Ethinyl Estradiol—osteoporosis	0.000714	0.00138	CcSEcCtD
Loxapine—Confusional state—Estradiol—osteoporosis	0.00071	0.00137	CcSEcCtD
Loxapine—Pruritus—Pamidronate—osteoporosis	0.000708	0.00137	CcSEcCtD
Loxapine—Oedema—Estradiol—osteoporosis	0.000704	0.00136	CcSEcCtD
Loxapine—Dizziness—Risedronate—osteoporosis	0.000696	0.00135	CcSEcCtD
Loxapine—Shock—Estradiol—osteoporosis	0.000693	0.00134	CcSEcCtD
Loxapine—Nervous system disorder—Estradiol—osteoporosis	0.000691	0.00134	CcSEcCtD
Loxapine—Tachycardia—Estradiol—osteoporosis	0.000687	0.00133	CcSEcCtD
Loxapine—Vomiting—Ethinyl Estradiol—osteoporosis	0.000686	0.00133	CcSEcCtD
Loxapine—Rash—Ethinyl Estradiol—osteoporosis	0.000681	0.00132	CcSEcCtD
Loxapine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.00068	0.00132	CcSEcCtD
Loxapine—Headache—Ethinyl Estradiol—osteoporosis	0.000676	0.00131	CcSEcCtD
Loxapine—Hypersensitivity—Zoledronate—osteoporosis	0.000673	0.0013	CcSEcCtD
Loxapine—Vomiting—Risedronate—osteoporosis	0.000669	0.0013	CcSEcCtD
Loxapine—Rash—Risedronate—osteoporosis	0.000664	0.00128	CcSEcCtD
Loxapine—Dermatitis—Risedronate—osteoporosis	0.000663	0.00128	CcSEcCtD
Loxapine—Dizziness—Pamidronate—osteoporosis	0.000662	0.00128	CcSEcCtD
Loxapine—Headache—Risedronate—osteoporosis	0.000659	0.00128	CcSEcCtD
Loxapine—Asthenia—Zoledronate—osteoporosis	0.000656	0.00127	CcSEcCtD
Loxapine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000648	0.00126	CcSEcCtD
Loxapine—Pruritus—Zoledronate—osteoporosis	0.000647	0.00125	CcSEcCtD
Loxapine—Nausea—Ethinyl Estradiol—osteoporosis	0.000641	0.00124	CcSEcCtD
Loxapine—Insomnia—Estradiol—osteoporosis	0.000637	0.00123	CcSEcCtD
Loxapine—Vomiting—Pamidronate—osteoporosis	0.000636	0.00123	CcSEcCtD
Loxapine—Paraesthesia—Estradiol—osteoporosis	0.000632	0.00122	CcSEcCtD
Loxapine—Asthenia—Conjugated Estrogens—osteoporosis	0.000631	0.00122	CcSEcCtD
Loxapine—Rash—Pamidronate—osteoporosis	0.000631	0.00122	CcSEcCtD
Loxapine—Dermatitis—Pamidronate—osteoporosis	0.00063	0.00122	CcSEcCtD
Loxapine—Dyspnoea—Estradiol—osteoporosis	0.000628	0.00122	CcSEcCtD
Loxapine—Headache—Pamidronate—osteoporosis	0.000627	0.00121	CcSEcCtD
Loxapine—Somnolence—Estradiol—osteoporosis	0.000626	0.00121	CcSEcCtD
Loxapine—Nausea—Risedronate—osteoporosis	0.000625	0.00121	CcSEcCtD
Loxapine—Pruritus—Conjugated Estrogens—osteoporosis	0.000623	0.00121	CcSEcCtD
Loxapine—Gastrointestinal disorder—Estradiol—osteoporosis	0.000608	0.00118	CcSEcCtD
Loxapine—Fatigue—Estradiol—osteoporosis	0.000607	0.00118	CcSEcCtD
Loxapine—Dizziness—Zoledronate—osteoporosis	0.000604	0.00117	CcSEcCtD
Loxapine—Constipation—Estradiol—osteoporosis	0.000602	0.00117	CcSEcCtD
Loxapine—Nausea—Pamidronate—osteoporosis	0.000594	0.00115	CcSEcCtD
Loxapine—Dizziness—Conjugated Estrogens—osteoporosis	0.000582	0.00113	CcSEcCtD
Loxapine—Vomiting—Zoledronate—osteoporosis	0.000581	0.00113	CcSEcCtD
Loxapine—Feeling abnormal—Estradiol—osteoporosis	0.00058	0.00112	CcSEcCtD
Loxapine—Rash—Zoledronate—osteoporosis	0.000576	0.00112	CcSEcCtD
Loxapine—Dermatitis—Zoledronate—osteoporosis	0.000576	0.00111	CcSEcCtD
Loxapine—Headache—Zoledronate—osteoporosis	0.000572	0.00111	CcSEcCtD
Loxapine—Vomiting—Conjugated Estrogens—osteoporosis	0.000559	0.00108	CcSEcCtD
Loxapine—Rash—Conjugated Estrogens—osteoporosis	0.000555	0.00107	CcSEcCtD
Loxapine—Dermatitis—Conjugated Estrogens—osteoporosis	0.000554	0.00107	CcSEcCtD
Loxapine—Headache—Conjugated Estrogens—osteoporosis	0.000551	0.00107	CcSEcCtD
Loxapine—Nausea—Zoledronate—osteoporosis	0.000543	0.00105	CcSEcCtD
Loxapine—Nausea—Conjugated Estrogens—osteoporosis	0.000523	0.00101	CcSEcCtD
Loxapine—Hypersensitivity—Estradiol—osteoporosis	0.000519	0.001	CcSEcCtD
Loxapine—Asthenia—Estradiol—osteoporosis	0.000505	0.000978	CcSEcCtD
Loxapine—Pruritus—Estradiol—osteoporosis	0.000498	0.000965	CcSEcCtD
Loxapine—Dizziness—Estradiol—osteoporosis	0.000466	0.000902	CcSEcCtD
Loxapine—Vomiting—Estradiol—osteoporosis	0.000448	0.000867	CcSEcCtD
Loxapine—Rash—Estradiol—osteoporosis	0.000444	0.00086	CcSEcCtD
Loxapine—Dermatitis—Estradiol—osteoporosis	0.000444	0.000859	CcSEcCtD
Loxapine—Headache—Estradiol—osteoporosis	0.000441	0.000854	CcSEcCtD
Loxapine—Nausea—Estradiol—osteoporosis	0.000418	0.00081	CcSEcCtD
Loxapine—ADRA1B—Signaling Pathways—ADCY5—osteoporosis	2.61e-05	7.48e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—ESR1—osteoporosis	2.61e-05	7.47e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—POMC—osteoporosis	2.6e-05	7.47e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IGF1—osteoporosis	2.6e-05	7.45e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling by GPCR—IL6—osteoporosis	2.6e-05	7.44e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—MTHFR—osteoporosis	2.58e-05	7.4e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6R—osteoporosis	2.58e-05	7.4e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—ADCY5—osteoporosis	2.58e-05	7.39e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—ESR1—osteoporosis	2.57e-05	7.37e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—POMC—osteoporosis	2.57e-05	7.37e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—GPX1—osteoporosis	2.57e-05	7.36e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—SPP1—osteoporosis	2.57e-05	7.36e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IRS1—osteoporosis	2.55e-05	7.33e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IGF1—osteoporosis	2.55e-05	7.3e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6R—osteoporosis	2.54e-05	7.28e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—SPP1—osteoporosis	2.53e-05	7.24e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IRS2—osteoporosis	2.51e-05	7.19e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6R—osteoporosis	2.51e-05	7.19e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IGF1—osteoporosis	2.5e-05	7.18e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IRS2—osteoporosis	2.48e-05	7.12e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IGF1—osteoporosis	2.47e-05	7.09e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—POMC—osteoporosis	2.46e-05	7.05e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—LEP—osteoporosis	2.45e-05	7.03e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IRS1—osteoporosis	2.43e-05	6.98e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—LEP—osteoporosis	2.43e-05	6.97e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—ADCY5—osteoporosis	2.41e-05	6.9e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IRS1—osteoporosis	2.4e-05	6.89e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6R—osteoporosis	2.4e-05	6.88e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IRS2—osteoporosis	2.4e-05	6.88e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IRS2—osteoporosis	2.39e-05	6.84e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—MTHFR—osteoporosis	2.37e-05	6.79e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—ADCY5—osteoporosis	2.37e-05	6.79e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IGF1—osteoporosis	2.37e-05	6.79e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—ADCY5—osteoporosis	2.36e-05	6.77e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—ADCY5—osteoporosis	2.36e-05	6.75e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—ADCY5—osteoporosis	2.35e-05	6.73e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—LEP—osteoporosis	2.35e-05	6.73e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—POMC—osteoporosis	2.34e-05	6.72e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—ESR1—osteoporosis	2.34e-05	6.72e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—LEP—osteoporosis	2.33e-05	6.69e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—POMC—osteoporosis	2.33e-05	6.69e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—SPP1—osteoporosis	2.33e-05	6.68e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—ADCY5—osteoporosis	2.32e-05	6.67e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—ESR1—osteoporosis	2.32e-05	6.65e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IRS2—osteoporosis	2.32e-05	6.65e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—ADCY5—osteoporosis	2.32e-05	6.65e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—POMC—osteoporosis	2.31e-05	6.63e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—MYC—osteoporosis	2.3e-05	6.61e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—TGFB1—osteoporosis	2.3e-05	6.59e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—SPP1—osteoporosis	2.29e-05	6.57e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6R—osteoporosis	2.29e-05	6.56e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—SPP1—osteoporosis	2.29e-05	6.55e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IRS2—osteoporosis	2.28e-05	6.55e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—SPP1—osteoporosis	2.28e-05	6.53e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—SPP1—osteoporosis	2.27e-05	6.51e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—LEP—osteoporosis	2.27e-05	6.51e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6R—osteoporosis	2.26e-05	6.47e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IGF1—osteoporosis	2.25e-05	6.47e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—SPP1—osteoporosis	2.25e-05	6.45e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—SPP1—osteoporosis	2.24e-05	6.43e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—ESR1—osteoporosis	2.24e-05	6.42e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—LEP—osteoporosis	2.23e-05	6.41e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—ESR1—osteoporosis	2.23e-05	6.39e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IGF1—osteoporosis	2.22e-05	6.38e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IRS1—osteoporosis	2.19e-05	6.28e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IRS1—osteoporosis	2.17e-05	6.22e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—ESR1—osteoporosis	2.17e-05	6.22e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—ADCY5—osteoporosis	2.15e-05	6.18e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—ESR1—osteoporosis	2.13e-05	6.12e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—POMC—osteoporosis	2.11e-05	6.04e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IRS2—osteoporosis	2.11e-05	6.04e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IRS1—osteoporosis	2.09e-05	6e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—POMC—osteoporosis	2.09e-05	5.99e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—SPP1—osteoporosis	2.08e-05	5.98e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IRS1—osteoporosis	2.08e-05	5.97e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IRS2—osteoporosis	2.07e-05	5.94e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IRS2—osteoporosis	2.07e-05	5.93e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—POMC—osteoporosis	2.07e-05	5.92e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IRS2—osteoporosis	2.06e-05	5.91e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—LEP—osteoporosis	2.06e-05	5.91e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6R—osteoporosis	2.06e-05	5.9e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IRS2—osteoporosis	2.05e-05	5.89e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—MYC—osteoporosis	2.05e-05	5.89e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—TGFB1—osteoporosis	2.05e-05	5.87e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—MYC—osteoporosis	2.04e-05	5.85e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6R—osteoporosis	2.04e-05	5.84e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—TGFB1—osteoporosis	2.03e-05	5.83e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IRS2—osteoporosis	2.03e-05	5.83e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IRS2—osteoporosis	2.03e-05	5.82e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—LEP—osteoporosis	2.03e-05	5.81e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IGF1—osteoporosis	2.03e-05	5.81e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IRS1—osteoporosis	2.03e-05	5.81e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—LEP—osteoporosis	2.02e-05	5.8e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—LEP—osteoporosis	2.02e-05	5.78e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—POMC—osteoporosis	2.02e-05	5.78e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—LEP—osteoporosis	2.01e-05	5.76e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IGF1—osteoporosis	2.01e-05	5.76e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—POMC—osteoporosis	2.01e-05	5.75e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling by GPCR—IL6—osteoporosis	2e-05	5.74e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling by GPCR—IL6—osteoporosis	2e-05	5.74e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IRS1—osteoporosis	1.99e-05	5.72e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—LEP—osteoporosis	1.99e-05	5.71e-05	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—IL6—osteoporosis	1.99e-05	5.71e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—IL6—osteoporosis	1.99e-05	5.7e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—LEP—osteoporosis	1.99e-05	5.69e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—ESR1—osteoporosis	1.97e-05	5.64e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6R—osteoporosis	1.97e-05	5.64e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6R—osteoporosis	1.96e-05	5.61e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—POMC—osteoporosis	1.95e-05	5.59e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling by GPCR—IL6—osteoporosis	1.95e-05	5.58e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IGF1—osteoporosis	1.94e-05	5.56e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—ESR1—osteoporosis	1.94e-05	5.55e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—ESR1—osteoporosis	1.93e-05	5.54e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IGF1—osteoporosis	1.93e-05	5.53e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—ESR1—osteoporosis	1.93e-05	5.52e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—POMC—osteoporosis	1.92e-05	5.5e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—ESR1—osteoporosis	1.92e-05	5.5e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—IL6—osteoporosis	1.92e-05	5.49e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6R—osteoporosis	1.9e-05	5.46e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—ESR1—osteoporosis	1.9e-05	5.45e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—ESR1—osteoporosis	1.9e-05	5.43e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—POMC—osteoporosis	1.89e-05	5.43e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—IL6—osteoporosis	1.89e-05	5.42e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IRS2—osteoporosis	1.88e-05	5.4e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IGF1—osteoporosis	1.88e-05	5.38e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6R—osteoporosis	1.87e-05	5.37e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IGF1—osteoporosis	1.85e-05	5.3e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—LEP—osteoporosis	1.84e-05	5.29e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IRS1—osteoporosis	1.84e-05	5.27e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—IL6—osteoporosis	1.81e-05	5.19e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IRS1—osteoporosis	1.81e-05	5.19e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IRS1—osteoporosis	1.8e-05	5.17e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IRS1—osteoporosis	1.8e-05	5.16e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IRS1—osteoporosis	1.79e-05	5.14e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IRS1—osteoporosis	1.78e-05	5.09e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IRS1—osteoporosis	1.77e-05	5.08e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—POMC—osteoporosis	1.77e-05	5.08e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—ESR1—osteoporosis	1.76e-05	5.05e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—POMC—osteoporosis	1.74e-05	4.99e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—POMC—osteoporosis	1.74e-05	4.98e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—IL6—osteoporosis	1.73e-05	4.97e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—POMC—osteoporosis	1.73e-05	4.97e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—POMC—osteoporosis	1.73e-05	4.95e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6R—osteoporosis	1.73e-05	4.95e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—IL6—osteoporosis	1.72e-05	4.94e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—POMC—osteoporosis	1.71e-05	4.9e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—POMC—osteoporosis	1.71e-05	4.89e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IGF1—osteoporosis	1.7e-05	4.88e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—IL6—osteoporosis	1.7e-05	4.88e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6R—osteoporosis	1.7e-05	4.87e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6R—osteoporosis	1.7e-05	4.86e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6R—osteoporosis	1.69e-05	4.85e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6R—osteoporosis	1.68e-05	4.83e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IGF1—osteoporosis	1.68e-05	4.8e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IGF1—osteoporosis	1.67e-05	4.79e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6R—osteoporosis	1.67e-05	4.78e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IGF1—osteoporosis	1.67e-05	4.78e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6R—osteoporosis	1.66e-05	4.77e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IGF1—osteoporosis	1.66e-05	4.76e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IRS1—osteoporosis	1.65e-05	4.72e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IGF1—osteoporosis	1.64e-05	4.72e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IGF1—osteoporosis	1.64e-05	4.7e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—POMC—osteoporosis	1.58e-05	4.54e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—MYC—osteoporosis	1.57e-05	4.51e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—MYC—osteoporosis	1.57e-05	4.51e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TGFB1—osteoporosis	1.57e-05	4.5e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TGFB1—osteoporosis	1.57e-05	4.5e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—MYC—osteoporosis	1.56e-05	4.48e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TGFB1—osteoporosis	1.56e-05	4.47e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—IL6—osteoporosis	1.55e-05	4.45e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6R—osteoporosis	1.55e-05	4.43e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—IL6—osteoporosis	1.54e-05	4.42e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—IL6—osteoporosis	1.54e-05	4.4e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—IL6—osteoporosis	1.53e-05	4.4e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—MYC—osteoporosis	1.53e-05	4.39e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TGFB1—osteoporosis	1.53e-05	4.38e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IGF1—osteoporosis	1.52e-05	4.37e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—MYC—osteoporosis	1.51e-05	4.32e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TGFB1—osteoporosis	1.5e-05	4.31e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—MYC—osteoporosis	1.49e-05	4.26e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—IL6—osteoporosis	1.48e-05	4.25e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TGFB1—osteoporosis	1.48e-05	4.25e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—IL6—osteoporosis	1.48e-05	4.23e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—IL6—osteoporosis	1.43e-05	4.11e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—MYC—osteoporosis	1.42e-05	4.08e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TGFB1—osteoporosis	1.42e-05	4.07e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—IL6—osteoporosis	1.41e-05	4.05e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MYC—osteoporosis	1.36e-05	3.89e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TGFB1—osteoporosis	1.35e-05	3.88e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MYC—osteoporosis	1.34e-05	3.83e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TGFB1—osteoporosis	1.33e-05	3.82e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—IL6—osteoporosis	1.3e-05	3.73e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—IL6—osteoporosis	1.28e-05	3.67e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—IL6—osteoporosis	1.28e-05	3.67e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—IL6—osteoporosis	1.27e-05	3.65e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—IL6—osteoporosis	1.27e-05	3.64e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—IL6—osteoporosis	1.26e-05	3.61e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—IL6—osteoporosis	1.25e-05	3.6e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MYC—osteoporosis	1.22e-05	3.49e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TGFB1—osteoporosis	1.22e-05	3.48e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MYC—osteoporosis	1.21e-05	3.46e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TGFB1—osteoporosis	1.2e-05	3.45e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—osteoporosis	1.18e-05	3.39e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—osteoporosis	1.18e-05	3.39e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—osteoporosis	1.17e-05	3.37e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—osteoporosis	1.17e-05	3.34e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MYC—osteoporosis	1.17e-05	3.34e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TGFB1—osteoporosis	1.16e-05	3.33e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MYC—osteoporosis	1.16e-05	3.32e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TGFB1—osteoporosis	1.16e-05	3.32e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—osteoporosis	1.15e-05	3.3e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—osteoporosis	1.13e-05	3.24e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MYC—osteoporosis	1.13e-05	3.23e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TGFB1—osteoporosis	1.12e-05	3.23e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—osteoporosis	1.12e-05	3.2e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MYC—osteoporosis	1.11e-05	3.18e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TGFB1—osteoporosis	1.11e-05	3.17e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—osteoporosis	1.07e-05	3.07e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MYC—osteoporosis	1.02e-05	2.93e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TGFB1—osteoporosis	1.02e-05	2.93e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—osteoporosis	1.02e-05	2.92e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MYC—osteoporosis	1.01e-05	2.89e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—osteoporosis	1.01e-05	2.88e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MYC—osteoporosis	1e-05	2.88e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TGFB1—osteoporosis	1e-05	2.88e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TGFB1—osteoporosis	1e-05	2.87e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MYC—osteoporosis	1e-05	2.87e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TGFB1—osteoporosis	9.99e-06	2.86e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MYC—osteoporosis	9.98e-06	2.86e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TGFB1—osteoporosis	9.96e-06	2.86e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MYC—osteoporosis	9.88e-06	2.83e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TGFB1—osteoporosis	9.86e-06	2.83e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MYC—osteoporosis	9.86e-06	2.83e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TGFB1—osteoporosis	9.83e-06	2.82e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MYC—osteoporosis	9.16e-06	2.63e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—osteoporosis	9.16e-06	2.63e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TGFB1—osteoporosis	9.14e-06	2.62e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—osteoporosis	9.07e-06	2.6e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—osteoporosis	8.76e-06	2.51e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—osteoporosis	8.71e-06	2.5e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—osteoporosis	8.48e-06	2.43e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—osteoporosis	8.34e-06	2.39e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—osteoporosis	7.69e-06	2.21e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—osteoporosis	7.57e-06	2.17e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—osteoporosis	7.55e-06	2.17e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—osteoporosis	7.53e-06	2.16e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—osteoporosis	7.5e-06	2.15e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—osteoporosis	7.43e-06	2.13e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—osteoporosis	7.41e-06	2.12e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—osteoporosis	6.88e-06	1.97e-05	CbGpPWpGaD
